Smac Mimetic SM-164 Potentiates APO2L/TRAIL- and Doxorubicin-Mediated Anticancer Activity in Human Hepatocellular Carcinoma Cells

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Zhang, Shuijun ^a,b   Li, Gongquan ^a,b   Zhao, Yongfu ^a,b   Liu, Guangzhi ^c   Wang, Yu ^c   Ma, Xiuxian ^a,b   Li, Dexu ^a,b   Wu, Yang ^a,b   Lu, Jianfeng ^a,d  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b Key Lab of Hepatobiliary and Pancreatic Surgery and Digestive Organ Transplant of Henan Province   (China)

^c HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^d UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 9; DOXORUBICIN; INHIBITOR OF APOPTOSIS PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; SM 164; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SCREENING; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LIVER CELL CARCINOMA; MALE; MOLECULAR CLONING; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BICYCLO COMPOUNDS, HETEROCYCLIC; BIOMIMETICS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; CYTIDINE DEAMINASE; DOXORUBICIN; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MITOCHONDRIAL PROTEINS; MUSCLE PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRIAZOLES;

INTRACISTERNAL A-PARTICLES;

EID: 84871120623     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051461     Document Type: Article

References (40)

1. Brechot C, Gozuacik D, Murakami Y, Paterlini-Brechot P, (2000) Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin Cancer Biol 10: 211-231.
2. Pan Q, Liu B, Liu J, Cai R, Liu X, et al. (2008) Synergistic antitumor activity of XIAP-shRNA and APO2L/TRAIL expressed by oncolytic adenoviruses in experimental HCC. Acta Oncol 47: 135-144.
3. Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY, (2008) CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 27: 1749-1758.
4. You H, Ding W, Dang H, Jiang Y, Rountree CB, (2011) c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology 54: 879-889.
5. Omar HA, Sargeant AM, Weng JR, Wang D, Kulp SK, et al. (2006) Targeting of the Akt-nuclear factor-kappa B signaling network by [1-(4-chloro-3-nitrobenzenesulfonyl)-1H-indol-3-yl]-methanol (OSU-A9), a novel indole-3-carbinol derivative, in a mouse model of hepatocellular carcinoma. Mol Pharmacol 76: 957-968.
6. Gyrd-Hansen M, Meier P, (2010) IAPs from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer 10: 561-574.
7. Srinivasula S, Ashwell J, (2008) IAPs: what's in a name? Mol Cell 25 30: 123-135.
8. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, et al. (2008) IAP-targeted therapies for cancer. Oncogene 27: 6252-6275.
9. Shi YH, Ding WX, Zhou J, He JY, Xu Y, et al. (2008) Expression of X-linked inhibitor-of-apoptosis protein in hepatocellular carcinoma promotes metastasis and tumor recurrence. Hepatology 48: 497-507.
10. Augello C, Caruso L, Maggioni M, Donadon M, Montorsi M, et al. (2009) Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. BMC Cancer 9: 125.
11. Lu X, Lee M, Tran T, Block T, (2005) High level expression of apoptosis inhibitor in hepatoma cell line expressing Hepatitis B virus. Int J Med Sci 2: 30-35.
12. Yamaguchi Y, Shiraki K, Fuke H, Inoue T, Miyashita K, et al. (2005) Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death, Oncol Rep. 14: 1311-1316.
13. Petersen S, Wang L, Yalcin-Chin A, Li L, Peyton M, et al. (2007) Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 12: 445-456.
14. Vince JE, Wong WW, Khan N, Feltham R, Chau D, et al. (2007) IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 131: 682-693.
15. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, et al. (2007) IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 131: 669-681.
16. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, et al. (2004) A small molecule Smac mimic potentiates APO2L/TRAIL- and TNFalpha-mediated cell death. Science 305: 1471-1474.
17. Lu J, McEachern D, Sun H, Bai L, Peng Y, et al. (2011) Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with APO2L/TRAIL for cancer treatment. Mol Cancer Ther 10: 902-914.
18. Eckelman BP, Salvesen GS, (2006) The human anti-apoptotic proteins cIAP1 and cIAP2 bind but do not inhibit caspases. J Biol Chem 281: 3254-3260.
19. Mehrotra S, Languino LR, Raskett CM, Mercurio AM, Dohi T, et al. (2010) IAP regulation of metastasis. Cancer Cell 17: 53-64.
20. Gyrd-Hansen M, Meier P, (2010) IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer 10: 561-574.
21. Du C, Fang M, Li Y, Li L, Wang X, (2000) Smac, a Mitochondrial Protein that Promotes Cytochrome c-Dependent Caspase Activation by Eliminating IAP Inhibition. Cell 102: 33-42.
22. Shi Y, (2002) Mechanisms of Caspase Activation and Inhibition during Apoptosis. Mol Cell 9: 459-470.
23. Riedl S, Shi Y, (2004) Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 5: 897-907.
24. Sun H, Nikolovska-Coleska Z, Yang CY, Xu L, Tomita Y, et al. (2004) Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site. J Med Chem 47: 4147-4150.
25. Zobel K, Wang L, Varfolomeev E, Franklin MC, Elliott LO, et al. (2006) Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs. ACS Chem Biol 1: 525-533.
26. Sun H, Nikolovska-Coleska Z, Lu J, Meagher JL, Yang CY, et al. (2007) Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. J Am Chem Soc 129: 15279-15294.
27. Lu J, Bai L, Sun H, Nikolovska-Coleska Z, McEachern D, et al. (2008) SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res 68: 9384-9393.
28. Fakler M, Loeder S, Vogler M, Schneider K, Jeremias I, et al. (2009) Small molecule XIAP inhibitors cooperate with APO2L/TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood 113: 1710-1722.
29. Cheung HH, Mahoney DJ, Lacasse EC, Korneluk RG, (2009) Down-regulation of c-FLIP Enhances death of cancer cells by smac mimetic compound. Cancer Res 69: 7729-7738.
30. Bockbrader KM, Tan M, Sun Y, (2005) A small molecule Smac-mimic compound induces apoptosis and sensitizes APO2L/TRAIL- and etoposide-induced apoptosis in breast cancer cells. Oncogene 24: 7381-7388.
31. Greer R, Peyton M, Larsen J, Girard L, Xie Y, et al. (2011) SMAC mimetic (JP1201) sensitizes non small cell lung cancers to multiple chemotherapy agents in an IAP dependent but TNFα independent manner. Cancer Res 71: 7640-7648.
32. Dineen S, Roland C, Greer R, Carbon J, Toombs J, et al. (2010) Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Cancer Res 70: 2852-2861.
33. Probst B, Liu L, Ramesh V, Li L, Sun H, et al. (2010) Smac mimetics increase cancer cell response to chemotherapeutics in a TNF-α-dependent manner. Cell Death Differ 17: 1645-1654.
34. Weisberg E, Kung A, Wright R, Moreno D, Catley L, et al. (2007) Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Mol Cancer Ther 6: 1951-1961.
35. Fandy TE, Shankar S, Ross DD, Sausville E, Srivastava RK, (2005) Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 7: 646-657.
36. Yang TS, Wang CH, Hsieh RK, Chen JS, Fung MC, (2002) Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial. Ann Oncol 13: 1771-1778.
37. Asghar U, Meyer T, (2012) Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? J Hepatol 56: 686-695.
38. Whittaker S, Marais R, Zhu AX, (2010) The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29: 4989-5005.
39. Bauer JA, Lupica JA, Schmidt H, Morrison BH, Haney RM, et al. (2007) Nitrosylcobalamin potentiates the anti-Neoplastic effects of chemotherapeutic agents via suppression of survival signaling. PLoS One 12: 1310-1321.
40. Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, et al. (2011) Lupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation. Hepatology 53: 160-170.